Activate and resist: L576P-KIT in GIST

Elena Conca, Tiziana Negri, Alessandro Gronchi, Elena Fumagalli, Elena Tamborini, Giovanni Maria Pavan, Maurizio Fermeglia, Marco A. Pierotti, Sabrina Pricl, Silvana Pilotti

Research output: Contribution to journalArticle

Abstract

L576P is a rare KIT mutation often reported in cancers other than gastrointestinal stromal tumors (GIST). In GISTs, it correlates with features linked to an aggressive phenotype, eventually resulting in secondary mutations. In vitro findings point out that L576P/KIT is constitutively activated,and shows poor imatinib sensitivity. In this work, histological,i mmunohistochemical,a nd biochemical analyses, coupled with mutational-molecular analysis and fluorescence in situ hybridization, were applied to surgical specimens. In parallel, the affinities of wild-type, L576P/KIT, and Δ559/KIT for imatinib were estimated by in silico studies. Despite imatinib treatment and the apparent clinical-imaging response, the detected histological response was very low. KIT resulted, expressed and activated in absence of secondary mutations, BRAF/NRAS mutations, an d KIT/PDGFRA gene alterations. Computer modeling proved that L576P/KIT is two times less sensitive than the wild-type counterpart and considerably less affine to imatinib than the sensitive Δ559/KIT. Accordingly, the modeling evidence strongly supports the lack of tumoral regression we observed at the histological level.

Original languageEnglish
Pages (from-to)2491-2495
Number of pages5
JournalMolecular Cancer Therapeutics
Volume8
Issue number9
DOIs
Publication statusPublished - Sep 1 2009

Fingerprint

Gastrointestinal Stromal Tumors
Mutation
Fluorescence In Situ Hybridization
Computer Simulation
Phenotype
Imatinib Mesylate
Genes
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Activate and resist : L576P-KIT in GIST. / Conca, Elena; Negri, Tiziana; Gronchi, Alessandro; Fumagalli, Elena; Tamborini, Elena; Pavan, Giovanni Maria; Fermeglia, Maurizio; Pierotti, Marco A.; Pricl, Sabrina; Pilotti, Silvana.

In: Molecular Cancer Therapeutics, Vol. 8, No. 9, 01.09.2009, p. 2491-2495.

Research output: Contribution to journalArticle

Conca, E, Negri, T, Gronchi, A, Fumagalli, E, Tamborini, E, Pavan, GM, Fermeglia, M, Pierotti, MA, Pricl, S & Pilotti, S 2009, 'Activate and resist: L576P-KIT in GIST', Molecular Cancer Therapeutics, vol. 8, no. 9, pp. 2491-2495. https://doi.org/10.1158/1535-7163.MCT-09-0662
Conca, Elena ; Negri, Tiziana ; Gronchi, Alessandro ; Fumagalli, Elena ; Tamborini, Elena ; Pavan, Giovanni Maria ; Fermeglia, Maurizio ; Pierotti, Marco A. ; Pricl, Sabrina ; Pilotti, Silvana. / Activate and resist : L576P-KIT in GIST. In: Molecular Cancer Therapeutics. 2009 ; Vol. 8, No. 9. pp. 2491-2495.
@article{79f10b421d9843dc9154461e8603cb26,
title = "Activate and resist: L576P-KIT in GIST",
abstract = "L576P is a rare KIT mutation often reported in cancers other than gastrointestinal stromal tumors (GIST). In GISTs, it correlates with features linked to an aggressive phenotype, eventually resulting in secondary mutations. In vitro findings point out that L576P/KIT is constitutively activated,and shows poor imatinib sensitivity. In this work, histological,i mmunohistochemical,a nd biochemical analyses, coupled with mutational-molecular analysis and fluorescence in situ hybridization, were applied to surgical specimens. In parallel, the affinities of wild-type, L576P/KIT, and Δ559/KIT for imatinib were estimated by in silico studies. Despite imatinib treatment and the apparent clinical-imaging response, the detected histological response was very low. KIT resulted, expressed and activated in absence of secondary mutations, BRAF/NRAS mutations, an d KIT/PDGFRA gene alterations. Computer modeling proved that L576P/KIT is two times less sensitive than the wild-type counterpart and considerably less affine to imatinib than the sensitive Δ559/KIT. Accordingly, the modeling evidence strongly supports the lack of tumoral regression we observed at the histological level.",
author = "Elena Conca and Tiziana Negri and Alessandro Gronchi and Elena Fumagalli and Elena Tamborini and Pavan, {Giovanni Maria} and Maurizio Fermeglia and Pierotti, {Marco A.} and Sabrina Pricl and Silvana Pilotti",
year = "2009",
month = "9",
day = "1",
doi = "10.1158/1535-7163.MCT-09-0662",
language = "English",
volume = "8",
pages = "2491--2495",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Activate and resist

T2 - L576P-KIT in GIST

AU - Conca, Elena

AU - Negri, Tiziana

AU - Gronchi, Alessandro

AU - Fumagalli, Elena

AU - Tamborini, Elena

AU - Pavan, Giovanni Maria

AU - Fermeglia, Maurizio

AU - Pierotti, Marco A.

AU - Pricl, Sabrina

AU - Pilotti, Silvana

PY - 2009/9/1

Y1 - 2009/9/1

N2 - L576P is a rare KIT mutation often reported in cancers other than gastrointestinal stromal tumors (GIST). In GISTs, it correlates with features linked to an aggressive phenotype, eventually resulting in secondary mutations. In vitro findings point out that L576P/KIT is constitutively activated,and shows poor imatinib sensitivity. In this work, histological,i mmunohistochemical,a nd biochemical analyses, coupled with mutational-molecular analysis and fluorescence in situ hybridization, were applied to surgical specimens. In parallel, the affinities of wild-type, L576P/KIT, and Δ559/KIT for imatinib were estimated by in silico studies. Despite imatinib treatment and the apparent clinical-imaging response, the detected histological response was very low. KIT resulted, expressed and activated in absence of secondary mutations, BRAF/NRAS mutations, an d KIT/PDGFRA gene alterations. Computer modeling proved that L576P/KIT is two times less sensitive than the wild-type counterpart and considerably less affine to imatinib than the sensitive Δ559/KIT. Accordingly, the modeling evidence strongly supports the lack of tumoral regression we observed at the histological level.

AB - L576P is a rare KIT mutation often reported in cancers other than gastrointestinal stromal tumors (GIST). In GISTs, it correlates with features linked to an aggressive phenotype, eventually resulting in secondary mutations. In vitro findings point out that L576P/KIT is constitutively activated,and shows poor imatinib sensitivity. In this work, histological,i mmunohistochemical,a nd biochemical analyses, coupled with mutational-molecular analysis and fluorescence in situ hybridization, were applied to surgical specimens. In parallel, the affinities of wild-type, L576P/KIT, and Δ559/KIT for imatinib were estimated by in silico studies. Despite imatinib treatment and the apparent clinical-imaging response, the detected histological response was very low. KIT resulted, expressed and activated in absence of secondary mutations, BRAF/NRAS mutations, an d KIT/PDGFRA gene alterations. Computer modeling proved that L576P/KIT is two times less sensitive than the wild-type counterpart and considerably less affine to imatinib than the sensitive Δ559/KIT. Accordingly, the modeling evidence strongly supports the lack of tumoral regression we observed at the histological level.

UR - http://www.scopus.com/inward/record.url?scp=70349487536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349487536&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-09-0662

DO - 10.1158/1535-7163.MCT-09-0662

M3 - Article

C2 - 19723893

AN - SCOPUS:70349487536

VL - 8

SP - 2491

EP - 2495

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 9

ER -